Kathmandu. Scientists at Brazil’s Federal University of Rio de Janeiro have developed an experimental drug called polylaminin for patients with spinal cord paralysis. This has been shown to help the nerves that have been torn due to the injury to reconnect or regrow.
{{TAG_OPEN_strong_37}What is it and how does it work?
Technology: is a protein-based form of bioengineering. It stimulates nerves to grow and reorganize tissues by activating the body’s nervous system, just like in the embryonic stage.
Method: is given by injection near the site of spinal cord injury.
Success so far: Animals and humans
}
Animal Testing: According to a 2025 study, most of the dogs will be able to walk when this technology is used in pet dogs with serious injuries.
Trials in humans: Preliminary studies have reported that some patients are able to use their hands and feet. However, widespread and proven results are yet to come.
Challenges and Realities
It is too early to call this technology a “miracle” or a “complete cure”. Some of its main limitations are:
Certification remains: has yet to be approved by Brazil’s regulator for large-scale use.
Complex Surgery: The process of administering this drug is extremely complex. This requires skilled neurosurgeons and state-of-the-art hospitals.
Accessibility and Cost: This technology can be expensive and will take time to reach patients in poor and rural areas.
Although it has been touted on social media as the “perfect antidote to tuberculosis”, scientists consider it an “experimental breakthrough”. More human trials over the next 12 to 36 months will determine how safe and effective it is.
